Celldex Therapeutics CLDX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's EBITDA margin?
- Celldex Therapeutics (CLDX) reported EBITDA margin of -35,299.7% in Q1 2026.
- How has Celldex Therapeutics's EBITDA margin changed year-over-year?
- Celldex Therapeutics's EBITDA margin decreased by 1147.2% year-over-year, from -2,830.3% to -35,299.7%.
- What is the long-term trend for Celldex Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Celldex Therapeutics's EBITDA margin has grown at a 87.1% compound annual growth rate (CAGR), from -801.1% to -18,369.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.